[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_105":106},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","d57kjtvn2arbaj30kfxd0we3o","revision",2,"title","LeMaitre Vascular Inc 高管退休及董事会变动","originalTitle","LEMAITRE VASCULAR INC (0001158895) (Filer)","summary","LeMaitre Vascular Inc 宣布 David B. Roberts 将于 2026 年 12 月 31 日退休，但仍将继续担任董事至 2029 年。公司感谢其 29 年的高管服务并保留其董事会职务。","reason","source",{"_11":95,"_96":97,"_98":99,"_100":57,"_101":102,"_103":104},"links",{"_92":93,"_63":94},"publishedAt","2026-10-15T20:11:11.000Z","discoveredAt","2026-10-15T23:20:47.229Z","timelineAt","category","ai-products","tags",[88,89,90,91],"stockSymbols",[87],"score",30,"selected",false,"channel","news","story",{"_72":73,"_15":16},"x","readingMode","full","author","language","body",{"_83":-5,"_63":84,"_85":-5,"_86":40},"outline",[75,76],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fYdip45Mo5zM",{"_72":73,"_15":16},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","f9c3d840-3266-4fc4-94cd-b3c06e240912",{"_72":73,"_15":16},{"_11":81,"_78":82,"_80":14},{"_11":77,"_78":79,"_80":14},"sec-2","text"," ","level","sec-1","FORM 8-K","zh","

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

\n \n \n \n \n \n

Date of Report (Date of earliest event reported): October 09, 2026

LeMaitre Vascular, Inc.

(Exact name of Registrant as Specified in Its Charter)

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n	\n
Delaware	001-33092	04-2825458
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

63 Second Avenue
Burlington, Massachusetts		01803
(Address of Principal Executive Offices)		(Zip Code)

\n \n \n \n \n \n

Registrant’s Telephone Number, Including Area Code: 781 221-2266

\n \n \n \n \n \n

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n	\n
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.01 par value per share		LMAT		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On October 9, 2026, David B. Roberts notified LeMaitre Vascular, Inc. (the “Company”) of his intent to retire as an employee of the Company, including as its President, effective as of December 31, 2026. Mr. Roberts was reelected as a director at the Company’s 2026 Annual Meeting of Stockholders for a term ending in 2029, and Mr. Roberts intends to continue to serve on the Company’s Board of Directors following his retirement as President.

The Company thanks Mr. Roberts for his 29 years of executive service and is pleased to retain his Board-level services going forward.

Forward-Looking Statements

This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n
			LEMAITRE VASCULAR, INC.

Date:	October 15, 2026	By:	/s/Dorian P. LeBlanc
			Name: Dorian P. LeBlanc Title: Chief Financial Officer

","zhKind","complete","LMAT","政策与监管","退市","停复牌","公司与财报","aihot","/items/d57kjtvn2arbaj30kfxd0we3o","https://www.sec.gov/Archives/edgar/data/1158895/000119312526422885/0001193125-26-422885-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792368000&sig=7b6974b5a67903ec","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792368000&sig=85dc13f192a3fa85 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792368000&sig=7b2f7276301ea6d9 96w","changelogVersion","2026-10-01T08:00"]